NovaGo Therapeutics
NovaGo Therapeutics Raises $30M Series B for Spinal Cord Injury Study
NovaGo Therapeutics announced $30M in Series B financing on September 2, 2026. NovaGo Therapeutics raised a $30 million Series B led by Neurimmune and Pureos Bioventures to advance a proof-of-concept study in acute spinal cord injury.
Round details
The financing includes backing from Neurimmune, Pureos Bioventures. The company did not publish a valuation with the announcement.
- Round: Series B
- Capital announced: $30M
- Headquarters: Schlieren, Switzerland
How the company plans to use the capital
NovaGo will use the proceeds to advance its lead program into a proof-of-concept study in patients with acute spinal cord injury, a randomized, double-blind trial enrolling 120 patients across sites in Germany, Spain, and Switzerland. The equity round was complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.
Why this matters for GTM teams
The round moves an anti-Nogo-A biologic from a Phase 1 study toward a randomized, double-blind proof-of-concept study in acute spinal cord injury, with existing and new investors participating alongside the two lead investors.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: NovaGo Therapeutics Series B announcement.
Company Info
Investors (2)
Share
Related Reports
Wabi Raises $55M at $1.25B Valuation in IVP-Led Funding
Wabi announced $55 million in funding led by IVP at a $1.25 billion valuation, which it said will support continued product development and expansion.
StimCardio Raises $30M Series A for Wearable AF Therapeutic
StimCardio announced the closing of an oversubscribed $30 million Series A led by Metis Medtech, expected to fund the company through its planned NeuroPulse 2 pivotal study and preparation for an FDA De Novo submission.
Casap Raises $56M Series B for AI Agents in Financial Services
Casap raised a $56 million Series B led by Base10 Partners, with Experian and Synchrony participating, to advance its AI agent platform for financial services.
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started